IDEXX Laboratories Gestione

Gestione criteri di controllo 3/4

IDEXX Laboratories Il CEO è Jay Mazelsky, nominato in Jun2019, e ha un mandato di 5.42 anni. la retribuzione annua totale è $ 11.52M, composta da 8.7% di stipendio e 91.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.1% delle azioni della società, per un valore di MX$ 711.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.4 anni e 7.7 anni.

Informazioni chiave

Jay Mazelsky

Amministratore delegato

US$11.5m

Compenso totale

Percentuale dello stipendio del CEO	8.7%
Mandato del CEO	5.4yrs
Proprietà del CEO	0.1%
Durata media del management	5.4yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jay Mazelsky rispetto agli utili di IDEXX Laboratories?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$866m
Jun 30 2024	n/a	n/a	US$846m
Mar 31 2024	n/a	n/a	US$867m
Dec 31 2023	US$12m	US$1m	US$845m
Sep 30 2023	n/a	n/a	US$823m
Jun 30 2023	n/a	n/a	US$791m
Mar 31 2023	n/a	n/a	US$699m
Dec 31 2022	US$10m	US$1m	US$679m
Sep 30 2022	n/a	n/a	US$670m
Jun 30 2022	n/a	n/a	US$664m
Mar 31 2022	n/a	n/a	US$735m
Dec 31 2021	US$9m	US$977k	US$745m
Sep 30 2021	n/a	n/a	US$757m
Jun 30 2021	n/a	n/a	US$728m
Mar 31 2021	n/a	n/a	US$674m
Dec 31 2020	US$7m	US$814k	US$582m
Sep 30 2020	n/a	n/a	US$497m
Jun 30 2020	n/a	n/a	US$460m
Mar 31 2020	n/a	n/a	US$437m
Dec 31 2019	US$7m	US$632k	US$428m
Sep 30 2019	n/a	n/a	US$423m
Jun 30 2019	n/a	n/a	US$407m
Mar 31 2019	n/a	n/a	US$390m
Dec 31 2018	US$3m	US$555k	US$377m
Sep 30 2018	n/a	n/a	US$330m
Jun 30 2018	n/a	n/a	US$307m
Mar 31 2018	n/a	n/a	US$284m
Dec 31 2017	US$2m	US$469k	US$263m

Compensazione vs Mercato: La retribuzione totale di Jay ($USD 11.52M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 5.73M ).

Compensazione vs guadagni: La retribuzione di Jay è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jay Mazelsky (63 yo)

5.4yrs

Mandato

US$11,519,309

Compensazione

Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jonathan Mazelsky	President	5.4yrs	US$11.52m	0.10% MX$ 711.5m
Brian McKeon	CFO, Executive VP & Treasurer	10.8yrs	US$3.85m	0.060% MX$ 426.4m
Michael Lane	Executive VP and GM of Reference Laboratories & Information Technology	4.8yrs	US$2.92m	0.0086% MX$ 61.2m
John Hart	Senior Vice President of Global Operations	7.2yrs	Nessun dato	Nessun dato
Jeffery Chadbourne	Senior Vice President of Commercial Finance & Sales Operations	9.8yrs	Nessun dato	Nessun dato
Martin Smith	Executive VP & CTO	3.3yrs	Nessun dato	Nessun dato
Ken Grady	Senior VP & Chief Information Officer	8.8yrs	Nessun dato	Nessun dato
Sharon Underberg	Executive VP	no data	US$1.88m	0.0068% MX$ 48.7m
Michael Johnson	Executive VP & Chief Human Resources Officer	2.7yrs	Nessun dato	0.00022% MX$ 1.6m
George Fennell	Senior VP & Chief Revenue Officer	no data	Nessun dato	0.0084% MX$ 60.2m
Michael Erickson	Executive VP and GM of Point of Care Diagnostics & Telemedicine	no data	Nessun dato	0.013% MX$ 92.7m
Murthy Yerramilli	Senior Vice President of Research & Development	4.8yrs	Nessun dato	Nessun dato

5.4yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di IDXX * è esperto e expertise (durata media dell'incarico 5.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jonathan Mazelsky	President	5.1yrs	US$11.52m	0.10% MX$ 711.5m
M. Szostak	Independent Director	12.3yrs	US$367.66k	0.0074% MX$ 52.8m
Daniel Junius	Independent Director	10.7yrs	US$362.66k	0.0031% MX$ 22.2m
Bruce Claflin	Independent Director	9.3yrs	US$367.66k	0.0021% MX$ 15.0m
Stuart Essig	Independent Director	7.3yrs	US$350.16k	0.0024% MX$ 17.2m
Lawrence Kingsley	Independent Non-Executive Chairman	8.1yrs	US$495.02k	0.0096% MX$ 68.6m
Sophie Vandebroek	Independent Director	11.3yrs	US$335.16k	0.011% MX$ 78.3m
Irene Chang Britt	Independent Director	1.3yrs	US$258.89k	0.00025% MX$ 1.8m
Sam Samad	Independent Director	5.3yrs	US$342.66k	0% MX$ 0
Asha Collins	Independent Director	4yrs	US$335.16k	0.00095% MX$ 6.8m

7.7yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IDXX * sono considerati esperti (durata media dell'incarico 7.7 anni).

IDEXX Laboratories Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes

Independent Director recently sold Mex$4.7m worth of stock

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

Insufficient new directors

Insufficient new directors

Recent updates

IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.83 (vs US$2.55 in 3Q 2023)

Independent Director recently sold Mex$4.7m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$2.46 (vs US$2.70 in 2Q 2023)

IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Insufficient new directors

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold Mex$52m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Insufficient new directors

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold Mex$2.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

President recently sold Mex$81m worth of stock

Insider recently sold Mex$142m worth of stock

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Independent Director has left the company

Senior Advisor & Director recently sold Mex$5.5m worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold Mex$3.3m worth of stock

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media